Vertex: Strategic Growth Ahead
Vertex Pharmaceuticals Raises 2026 Revenue Guidance, Plans $10 Billion Crinetics Acquisition
Anonymous
Key Points
1
In Q2, Vertex's U.S. revenue was $2.06 billion, up 11%, while international revenue rose 14% to $1.28 billion, underscoring substantial growth outside the U.S.
2
Casgevy and Journavx combined for $126 million in Q2 revenue, up 75% from Q1, and they accounted for about 3.8% of Vertex's total sales.
3
Vertex plans to close its $10 billion Crinetics acquisition in Q3 2026 and held about $13.6 billion in cash and investments to support the deal; the deal would add a rare endocrine diseases focus and broaden the company's portfolio to a fifth pillar.
4
Q2 GAAP earnings were $1.1 billion with GAAP EPS of $4.31, and adjusted non-GAAP EPS of $4.73, roughly in line with consensus estimates of about $4.74.
5
Alyftrek contributed about $416.8 million of additional revenue year over year, while revenue from Trikafta and legacy CF products declined by roughly $110.5 million, illustrating ongoing mix shifts within Vertex's portfolio.
Vertex Pharmaceuticals posted $3.33 billion in Q2 2026 revenue, up 12% year over year, and raised its full-year guidance to $13.1–$13.2 billion, according to Seeking Alpha. The company also confirmed plans to close its $10 billion acquisition of Crinetics Pharmaceuticals in Q3 2026, a deal that would push Vertex into rare endocrine diseases.
Cystic fibrosis drugs still drove the vast majority of sales — about 96% — but newer products Casgevy and Journavx are gaining ground fast, per Guru Focus.
CF Drugs Lead Growth, But New Products Surge
Alyftrek, Vertex's newest cystic fibrosis therapy, added $416.8 million in revenue compared to the same period last year, according to Guru Focus. At the same time, older CF products like Trikafta saw a combined $110.5 million revenue decline. The mix is shifting inside Vertex's own portfolio.
U.S. revenue hit $2.06 billion, up 11%. International revenue rose 14% to $1.28 billion. That international growth shows Vertex is not just a domestic story, per Seeking Alpha.
Casgevy and Journavx Nearly Double From Q1
Casgevy, a gene therapy for sickle cell disease, and Journavx, a pain treatment, together brought in $126 million in Q2. That is up 75% from the $72 million they made in Q1, according to Guru Focus. Still, the two products made up only about 3.8% of total sales.
Vertex expects at least $500 million combined from Casgevy and Journavx for the full year. That target means the two drugs need to roughly triple their Q2 pace in the second half, as TS2 Tech noted, pointing to a steep 53% second-half hurdle for the non-CF portfolio.
$10 Billion Crinetics Deal Adds a Fifth Business Pillar
Vertex plans to buy Crinetics Pharmaceuticals for $10 billion and close the deal in Q3 2026, per Seeking Alpha. Crinetics focuses on rare endocrine diseases — conditions involving hormone-producing glands. Vertex calls this a fifth pillar for its business, beyond cystic fibrosis, pain, and gene therapies.
Vertex held about $13.6 billion in cash and investments at the end of Q2, giving it more than enough to fund the acquisition, according to Guru Focus. The deal signals that Vertex is betting on rare disease expertise as its long-term growth engine.
Earnings Land Near Forecasts, Stock Moves Little
GAAP net income for Q2 came in at $1.1 billion, with GAAP earnings per share of $4.31. On an adjusted basis, non-GAAP EPS was $4.73 — just a penny below the Wall Street consensus of about $4.74, per Seeking Alpha.
Vertex's stock moved only modestly after hours. The raised full-year guidance of $13.1–$13.2 billion — up $125 million from prior estimates — was in line with expectations rather than a big surprise, as TS2 Tech reported.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
20
Articles
112
Reach
132
A
AnonymousAuthor
